Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Head-To-Head Lung Data Support Boehringer’s Gilotrif Over Iressa

Executive Summary

Final results from the LUX-Lung 7 trial suggest superior efficacy for Boehringer’s EGFR inhibitor Gilotrif vs. AstraZeneca’s Iressa, albeit with a small absolute improvement in progression-free survival and a higher rate of severe diarrhea.

Advertisement

Related Content

Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
ESMO In Brief: PD-1 Updates, Perjeta’s Striking Survival, Boehringer’s Gilotrif Head-to-Head EGFR Data & More
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel